Amgen Inc. $AMGN Shares Purchased by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR increased its position in Amgen Inc. (NASDAQ:AMGN) by 9.5% in the third quarter, HoldingsChannel reports. The firm owned 53,401 shares of the medical research company’s stock after acquiring an additional 4,647 shares during the period. Generali Asset Management SPA SGR’s holdings in Amgen were worth $22,509,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. MW Advisory LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $1,054,000. Baird Financial Group Inc. lifted its position in shares of Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares in the last quarter. State Street Corp boosted its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. KBC Group NV boosted its holdings in shares of Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares during the period. Finally, Nilsine Partners LLC acquired a new stake in shares of Amgen during the second quarter worth approximately $3,329,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 0.7%

AMGN opened at $447.95 on Wednesday. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $450.98. The business has a 50-day moving average of $418.42 and a 200-day moving average of $372.80.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st.

Analysts Set New Price Targets

A number of brokerages recently commented on AMGN. Bank of America boosted their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research note on Friday. Truist Financial boosted their price target on shares of Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday, October 7th. Finally, Citigroup boosted their price target on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $389.71.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last quarter. Corporate insiders own 0.85% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The company will also present long-term data for UPLIZNA and real-world evidence for KRYSTEXXA and TAVNEOS, strengthening its rare-disease and autoimmune pipeline. Amgen ACR Convergence 2026 data
• Positive Sentiment: New Phase 3 data for Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi showed a 58% reduction in the risk of death in extensive-stage small-cell lung cancer, with median survival reaching 21.1 months. The results could improve the commercial outlook for Imdelltra, although execution and competition remain important considerations. Imdelltra and Imfinzi lung cancer results
• Positive Sentiment: Jefferies raised its Amgen price target to $428 from $410, while Barclays previously increased its target to $400 from $380. The revisions reflect improving sentiment around Amgen’s pipeline, though both targets remain below the current trading level. Jefferies raises Amgen price target
• Neutral Sentiment: Amgen appointed former Kimberly-Clark CEO David W. Gibbs to its board. The addition brings experienced leadership but is unlikely to materially change near-term earnings expectations. Amgen appoints David Gibbs
• Negative Sentiment: The FDA issued Amgen a warning letter over a promotional video for its Vectibix cancer drug, creating regulatory and compliance risk and potentially requiring corrective advertising. FDA warns Amgen over Vectibix promotional video
• Negative Sentiment: Some analysts caution that commercial uncertainties surrounding Imdelltra warrant a $328 price target and Underperform rating. Separately, Zacks said Amgen lacks key indicators supporting a likely earnings beat in next week’s report, increasing event risk ahead of results. Amgen analyst caution on Imdelltra

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.